AQST

Business Context and Reporting Period

Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company focused on developing innovative drug delivery technologies, primarily oral films. The company operates as a single segment, manufacturing licensed products (e.g., Suboxone) and developing proprietary candidates, most notably Anaphylm (epinephrine sublingual film for anaphylaxis) and Libervant (diazepam buccal film for epilepsy). This summary covers the fiscal year ended December 31, 2025.

Key Financial Metrics

Revenue Breakdown (2025): Manufacture and supply revenue was $40.2 million (up 1%), while license and royalty revenue dropped significantly to $3.5 million (down 77%) due to the absence of one-time deferred revenue recognitions from terminated agreements in the prior year. Proprietary product revenue was negative $(0.5) million due to return allowances for Libervant.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 23% primarily due to a $11.8 million drop in license and royalty revenue. This was driven by the one-time recognition of $11.5 million in deferred revenue in 2024 following the termination of licensing agreements (MTPA and Haisco), which did not recur in 2025.
• Expense Surge: Selling, General, and Administrative (SG&A) expenses increased 59% to $79.8 million. This was driven by approximately $14.3 million in legal expenses (including a confidential settlement), $9.6 million in commercial spending for Anaphylm launch preparation, and the $4.3 million Anaphylm PDUFA fee.
• Libervant Market Access Loss: In February 2025, a federal court vacated the FDA's approval of Libervant for patients aged 2–5 due to orphan drug exclusivity disputes with Neurelis. Consequently, the FDA converted the approval to "tentative," and Aquestive ceased U.S. marketing activities, resulting in negative proprietary product revenue for the year.
• Capital Raising: The company raised significant capital through a 2025 underwritten public offering ($79.9 million net) and At-The-Market (ATM) sales ($21.2 million net), increasing cash reserves from $71.5 million to $121.2 million.

Guidance, Outlook, and Risks

Regulatory Developments

• Anaphylm CRL: On January 30, 2026 (subsequent to year-end), the FDA issued a Complete Response Letter (CRL) for Anaphylm. The CRL cited deficiencies in Human Factors (HF) validation studies regarding pouch opening and film placement. The company plans to conduct new HF and PK studies and resubmit the NDA in Q3 2026.
• Libervant Litigation: The company is appealing the court decision vacating Libervant's approval. New legislation signed in February 2026 amended the Orphan Drug Act, potentially supporting the FDA's original interpretation, but the outcome remains uncertain.

Liquidity and Debt

• Debt Service: The company holds $45 million in 13.5% Senior Secured Notes. Interest-only payments continue until June 2026, at which point quarterly principal amortization begins. The company estimates it has sufficient liquidity for at least 12 months but will require additional capital to fund Anaphylm commercialization and debt service.
• RTW Agreement: In August 2025, the company entered a Purchase and Sale Agreement with RTW Investments for $75 million, contingent on Anaphylm approval and debt refinancing. This was amended in March 2026 to extend the approval deadline to June 30, 2027.

Risks

• Customer Concentration: Indivior accounted for 73% of 2025 revenue. The agreement is subject to annual renewal and potential termination.
• Going Concern: The company has a history of net losses and an accumulated deficit of $447 million. Continued profitability is not assured, and future financing may be required.
• Product Liability: The company is a defendant in multidistrict litigation regarding dental injuries associated with Suboxone, though Indivior has agreed to defend the company.

Investor Verification Checklist

• Anaphylm Resubmission Timeline: Verify the company's ability to complete the required Human Factors and PK studies and resubmit the NDA by Q3 2026 as planned.
• Libervant Legal Outcome: Monitor the DC Appellate Court proceedings regarding the Neurelis lawsuit and the impact of the new Orphan Drug Act legislation on market access.
• Debt Refinancing: Assess the feasibility of refinancing the 13.5% Notes before principal payments commence in June 2026 to avoid liquidity strain.
• Indivior Contract Renewal: Confirm the status of the Indivior license agreement renewal, given it represents the majority of current revenue.
• Capital Runway: Evaluate the sufficiency of the $121.2 million cash balance against the projected costs of Anaphylm commercialization and ongoing debt service obligations.